Ascendis Pharma A/S (NASDAQ:ASND) Shares Purchased by FIL Ltd

FIL Ltd lifted its position in Ascendis Pharma A/S (NASDAQ:ASND) by 13.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 729,275 shares of the biotechnology company’s stock after purchasing an additional 89,016 shares during the period. FIL Ltd owned about 1.20% of Ascendis Pharma A/S worth $100,399,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ASND. Legal & General Group Plc raised its position in Ascendis Pharma A/S by 1,577.6% during the fourth quarter. Legal & General Group Plc now owns 17,682 shares of the biotechnology company’s stock worth $2,433,000 after acquiring an additional 16,628 shares during the period. Trexquant Investment LP grew its holdings in shares of Ascendis Pharma A/S by 235.9% during the fourth quarter. Trexquant Investment LP now owns 27,067 shares of the biotechnology company’s stock worth $3,726,000 after buying an additional 19,010 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Ascendis Pharma A/S by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company’s stock worth $7,858,000 after buying an additional 629 shares in the last quarter. Schroder Investment Management Group grew its holdings in shares of Ascendis Pharma A/S by 14.5% during the fourth quarter. Schroder Investment Management Group now owns 92,728 shares of the biotechnology company’s stock worth $12,656,000 after buying an additional 11,739 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its holdings in shares of Ascendis Pharma A/S by 13.9% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 20,506 shares of the biotechnology company’s stock worth $2,823,000 after buying an additional 2,506 shares in the last quarter.

Ascendis Pharma A/S Stock Up 0.3 %

NASDAQ ASND opened at $137.84 on Thursday. The stock has a market capitalization of $8.37 billion, a P/E ratio of -19.41 and a beta of 0.54. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The firm has a 50-day moving average price of $147.39 and a 200 day moving average price of $137.68.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, equities research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on ASND. UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. The Goldman Sachs Group boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Cantor Fitzgerald boosted their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. Finally, Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $204.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.